CALML3

Summary

CALML3 (calmodulin like 3, HGNC:1452) is a protein-coding gene on chromosome 10p15.1, encoding Calmodulin-like protein 3 (P27482). May function as a specific light chain of unconventional myosin-10 (MYO10), also enhances MYO10 translation, possibly by acting as a chaperone for the emerging MYO10 heavy chain protein.

Predicted to enable calcium ion binding activity. Located in extracellular exosome.

Source: NCBI Gene 810 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 27 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005185

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1452
Approved symbol	CALML3
Name	calmodulin like 3
Location	10p15.1
Locus type	gene with protein product
Status	Approved
Aliases	CLP
Ensembl gene	ENSG00000178363
Ensembl biotype	protein_coding
OMIM	114184
Entrez	810

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000315238

RefSeq mRNA: 1 — MANE Select: NM_005185 NM_005185

CCDS: CCDS7069

Canonical transcript exons

ENST00000315238 — 1 exons

Exon	Start	End
ENSE00001234570	5524961	5526771

Expression profiles

Bgee: expression breadth ubiquitous, 177 present calls, max score 99.33.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 6.5547 / max 1765.8783, expressed in 100 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103644	6.5547	100

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.33	gold quality
gingiva	UBERON:0001828	99.27	gold quality
gingival epithelium	UBERON:0001949	99.20	gold quality
mammalian vulva	UBERON:0000997	99.00	gold quality
tongue squamous epithelium	UBERON:0006919	98.73	gold quality
esophagus mucosa	UBERON:0002469	98.64	gold quality
upper arm skin	UBERON:0004263	98.47	gold quality
pharyngeal mucosa	UBERON:0000355	98.21	gold quality
oral cavity	UBERON:0000167	97.68	gold quality
skin of leg	UBERON:0001511	96.92	gold quality
skin of abdomen	UBERON:0001416	96.60	gold quality
cervix epithelium	UBERON:0004801	96.29	gold quality
zone of skin	UBERON:0000014	96.17	gold quality
hair follicle	UBERON:0002073	96.11	gold quality
squamous epithelium	UBERON:0006914	96.09	gold quality
epithelium of esophagus	UBERON:0001976	96.01	gold quality
esophagus squamous epithelium	UBERON:0006920	96.00	gold quality
penis	UBERON:0000989	94.04	gold quality
body of tongue	UBERON:0011876	93.61	gold quality
nipple	UBERON:0002030	93.28	gold quality
upper leg skin	UBERON:0004262	93.24	gold quality
mouth mucosa	UBERON:0003729	92.42	gold quality
buccal mucosa cell	CL:0002336	91.97	gold quality
minor salivary gland	UBERON:0001830	91.39	gold quality
tongue	UBERON:0001723	91.28	gold quality
cervix squamous epithelium	UBERON:0006922	90.31	gold quality
saliva-secreting gland	UBERON:0001044	90.08	gold quality
vagina	UBERON:0000996	89.88	gold quality
tonsil	UBERON:0002372	86.85	gold quality
thymus	UBERON:0002370	86.13	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	1897.61
E-MTAB-10855	yes	1548.79
E-CURD-79	yes	1430.64
E-CURD-114	yes	143.48
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting CALML3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-6801-3P	98.04	64.64	805
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-4669	97.94	62.71	224
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-6894-3P	96.73	65.64	798
HSA-MIR-423-3P	95.99	67.75	62
HSA-MIR-6741-5P	93.86	63.06	437
HSA-MIR-4730	90.12	69.65	64

Literature-anchored findings (GeneRIF, showing 8)

• CLP may be required during terminal differentiation to increase myosin-10 function as cells migrate toward the upper layers and establish new adhesive contacts. (PMID:17130134)
• increased CLP expression and CLP-mediated Myo10 function are important for skin differentiation and wound reepithelialization (PMID:18818677)
• expression was readily detected in areas of normal oral mucosa, while a notable downregulation of expression occurred in areas of malignant transformation (PMID:19166543)
• Increased CALML3 expression in suprabasal layers is characteristic for differentiating keratinocytes in normal epidermis, and nuclear expression of CALML3 inversely correlates with expression of the proliferation marker Ki-67. (PMID:23638045)
• We identified calmodulin-like protein 3 (CALML3) as a key sensor of this SNP and a coregulator of ERalpha, which contributes to differential gene transcription regulation in an estrogen and SERM-dependent fashion. Furthermore, using CRISPR/Cas9-engineered ZR75-1 breast cancer cells with different ZNF423 SNP genotypes, striking differences in cellular responses to SERMs and PARP inhibitors, alone or in combination (PMID:28821270)
• UVB irradiation induced increase in apoptosis, Reactive Oxygen Species production and Ca2+ concentration of human lens epithelial cells , in part, by downregulating the expression of CALML3 and involved oxidative stress, Ca2+, JNK1/2 and ERK1/2 signaling pathways, suggesting that investigating CALML3 may useful for developing cataract treatment. (PMID:29436594)
• Loss of CALML3 predicts shorter overall and relapse-free survival in postoperative hepatocellular carcinoma (HCC) patients, thus providing a prognostic biomarker and therapy target in HCC. (PMID:29445139)
• Metformin suppresses gastric cancer through stimulating Calml3 secretion from TAFs. (PMID:30320344)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	calm1a	ENSDARG00000021811
danio_rerio	calm1b	ENSDARG00000034187
mus_musculus	Calml3	ENSMUSG00000063130
rattus_norvegicus	Calml3	ENSRNOG00000031955
drosophila_melanogaster	TpnC4	FBGN0033027
caenorhabditis_elegans		WBGENE00000285
caenorhabditis_elegans		WBGENE00000287
caenorhabditis_elegans	pat-10	WBGENE00003934
caenorhabditis_elegans		WBGENE00006583
caenorhabditis_elegans		WBGENE00008453
caenorhabditis_elegans	F35C12.3	WBGENE00009408
caenorhabditis_elegans		WBGENE00015264

Paralogs (20): CABP7 (ENSG00000100314), CABP5 (ENSG00000105507), CALML4 (ENSG00000129007), CALM2 (ENSG00000143933), CETN2 (ENSG00000147400), CETN3 (ENSG00000153140), CABP1 (ENSG00000157782), CALM3 (ENSG00000160014), CABP2 (ENSG00000167791), CALML6 (ENSG00000169885), EFCAB3 (ENSG00000172421), EFCAB12 (ENSG00000172771), CABP4 (ENSG00000175544), CETN1 (ENSG00000177143), CALML5 (ENSG00000178372), CALN1 (ENSG00000183166), CALM1 (ENSG00000198668), EFCAB2 (ENSG00000203666), EFCAB7 (ENSG00000203965), EFCAB9 (ENSG00000214360)

Protein

Protein identifiers

Calmodulin-like protein 3 — P27482 (reviewed: P27482)

Alternative names: CaM-like protein, Calmodulin-related protein NB-1

All UniProt accessions (1): P27482

UniProt curated annotations — full annotation on UniProt →

Function. May function as a specific light chain of unconventional myosin-10 (MYO10), also enhances MYO10 translation, possibly by acting as a chaperone for the emerging MYO10 heavy chain protein. May compete with calmodulin by binding, with different affinities, to cellular substrates.

Subunit / interactions. Interacts with MYO10, the interaction is calcium-dependent and essential for MYO10 function in filopodial extension.

Tissue specificity. Expressed in normal mammary, prostate, cervical, and epidermal tissues. It is greatly reduced or undetectable in transformed cells.

Induction. By TGFB1.

Miscellaneous. Binds four calcium ions.

Similarity. Belongs to the calmodulin family.

RefSeq proteins (1): NP_005176* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR050230	CALM/Myosin/TropC-like	Family

Pfam: PF13499

UniProt features (35 total): binding site 19, helix 7, domain 4, strand 4, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1GGZ	X-RAY DIFFRACTION	1.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P27482-F1	83.17	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (19): 57; 59; 61; 63; 68; 94; 96; 98; 105; 130; 132; 134 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 117 (showing top): JAEGER_METASTASIS_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, CREBP1_Q2, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_RESPONSE_TO_METAL_ION, SMITH_TERT_TARGETS_DN, GOBP_REGULATION_OF_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_MAINTENANCE_OF_LOCATION, GOCC_CENTROSOME, GOBP_SARCOPLASMIC_RETICULUM_CALCIUM_ION_TRANSPORT, KEGG_OLFACTORY_TRANSDUCTION, GOBP_DETECTION_OF_STIMULUS, GOBP_MONOATOMIC_ION_HOMEOSTASIS, GOBP_REGULATION_OF_RELEASE_OF_SEQUESTERED_CALCIUM_ION_INTO_CYTOSOL

GO Biological Process (3): detection of calcium ion (GO:0005513), regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880), calcineurin-mediated signaling (GO:0097720)

GO Molecular Function (3): calcium ion binding (GO:0005509), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): cytoplasm (GO:0005737), centrosome (GO:0005813), synaptic vesicle membrane (GO:0030672), myelin sheath (GO:0043209), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
detection of chemical stimulus	1
response to calcium ion	1
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	1
regulation of release of sequestered calcium ion into cytosol	1
calcium-mediated signaling	1
metal ion binding	1
binding	1
cation binding	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
synaptic vesicle	1
exocytic vesicle membrane	1
extracellular vesicle	1

Protein interactions and networks

STRING

7352 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CALML3	NOS3	P29474	996
CALML3	CALD1	Q05682	996
CALML3	NOS1	P29475	995
CALML3	MARCKS	P29966	995
CALML3	IQGAP1	P46940	994
CALML3	MYLK2	Q9H1R3	994
CALML3	CAMK2A	Q9UQM7	994
CALML3	MYLK	Q15746	993
CALML3	RYR2	Q92736	993
CALML3	NRGN	Q92686	992
CALML3	CACNA1C	Q13936	991
CALML3	RYR1	P21817	990
CALML3	TRPV1	Q8NER1	990
CALML3	CAMK4	Q16566	987
CALML3	MBP	P02686	987
CALML3	GAP43	P17677	987

IntAct

194 interactions, top by confidence:

A	B	Type	Score
POC5	CETN3	psi-mi:“MI:0914”(association)	0.920
POC5	CETN3	psi-mi:“MI:0914”(association)	0.770
EIF4E2	GIGYF1	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CALML3	MYO10	psi-mi:“MI:0915”(physical association)	0.680
CALML3	MYO10	psi-mi:“MI:0407”(direct interaction)	0.680
MYO10	CALML3	psi-mi:“MI:0407”(direct interaction)	0.680
CALML3	IQCN	psi-mi:“MI:0915”(physical association)	0.670
IQCN	CALML3	psi-mi:“MI:0915”(physical association)	0.670
ANXA9	PPL	psi-mi:“MI:0914”(association)	0.660
SINHCAF	TNRC18	psi-mi:“MI:0914”(association)	0.640
RAB11B	SH3BP5	psi-mi:“MI:0914”(association)	0.640
CAPZA2	CNOT1	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
CALML3	KIAA1683	psi-mi:“MI:0915”(physical association)	0.560
MFI	CALML3	psi-mi:“MI:0915”(physical association)	0.560
CALML3	MFI	psi-mi:“MI:0915”(physical association)	0.560
IQCB1	CALML3	psi-mi:“MI:0915”(physical association)	0.560
CALML3	IQCB1	psi-mi:“MI:0915”(physical association)	0.560
ZSCAN12	A2ML1	psi-mi:“MI:0914”(association)	0.530

BioGRID (264): KIAA1683 (Two-hybrid), C11orf65 (Two-hybrid), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), CALML3 (Affinity Capture-MS)

ESM2 similar proteins: A0A125YHX7, A0A125YZN2, J9W034, O15182, O23184, O35648, O74435, O82659, P02597, P02599, P04352, P05434, P05933, P06704, P27163, P27164, P27482, P41041, P41208, P41209, P41210, P43645, P43646, P49258, P53440, P53441, P54213, P60204, P60205, P60206, P61859, P61860, P61861, Q06827, Q12798, Q24956, Q27177, Q27178, Q27179, Q2TBN3

Diamond homologs: A4IF97, B7SNI3, F1SSF9, O14950, O23320, O93409, O96081, O97341, P02597, P02608, P02609, P02610, P02611, P02612, P02613, P04112, P04113, P04464, P04466, P05419, P05932, P05933, P05944, P05963, P07461, P08051, P08052, P08733, P10916, P11118, P11121, P13543, P13832, P13833, P14533, P18061, P18432, P18666, P19105, P19625

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	26
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

55 predictions. Top by Δscore:

Variant	Effect	Δscore
10:5525525:TGTCC:T	donor_gain	0.8700
10:5525149:AAG:A	acceptor_gain	0.8100
10:5525148:CA:C	acceptor_gain	0.7200
10:5525149:AA:A	acceptor_gain	0.7200
10:5525145:TGACA:T	acceptor_gain	0.6600
10:5525070:C:CA	acceptor_gain	0.6300
10:5525497:A:AG	donor_gain	0.5900
10:5525498:A:G	donor_gain	0.5900
10:5525495:TG:T	donor_gain	0.5800
10:5525526:GTCCA:G	donor_gain	0.5700
10:5525706:A:AG	acceptor_gain	0.5700
10:5525082:T:TA	acceptor_gain	0.4700
10:5525150:A:G	acceptor_gain	0.4600
10:5525149:A:AG	acceptor_gain	0.4500
10:5525496:G:A	donor_gain	0.4400
10:5525145:T:TA	acceptor_gain	0.4300
10:5525690:C:A	acceptor_gain	0.4100
10:5525505:G:GT	donor_gain	0.3900
10:5525531:A:G	donor_gain	0.3700
10:5525679:ATCCC:A	acceptor_gain	0.3600
10:5525683:C:A	acceptor_gain	0.3400
10:5525124:C:CT	acceptor_gain	0.3200
10:5525703:T:A	acceptor_gain	0.3200
10:5525086:AT:A	acceptor_gain	0.3100
10:5525707:C:G	acceptor_gain	0.3100
10:5525532:G:GG	donor_gain	0.3000
10:5525581:C:T	donor_gain	0.3000
10:5525070:C:G	acceptor_gain	0.2900
10:5525714:C:A	acceptor_gain	0.2800
10:5525739:T:G	acceptor_gain	0.2700

AlphaMissense

1000 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:5525134:T:C	F17L	0.993
10:5525136:C:A	F17L	0.993
10:5525136:C:G	F17L	0.993
10:5525290:T:C	F69L	0.991
10:5525292:C:A	F69L	0.991
10:5525292:C:G	F69L	0.991
10:5525168:T:A	I28N	0.988
10:5525353:T:C	F90L	0.988
10:5525355:C:A	F90L	0.988
10:5525355:C:G	F90L	0.988
10:5525387:T:A	V101D	0.988
10:5525231:T:C	L49P	0.985
10:5525291:T:C	F69S	0.985
10:5525198:G:C	R38P	0.984
10:5525402:T:C	L106P	0.983
10:5525200:T:C	S39P	0.982
10:5525168:T:C	I28T	0.981
10:5525362:T:C	F93L	0.980
10:5525364:C:A	F93L	0.980
10:5525364:C:G	F93L	0.980
10:5525143:T:C	F20L	0.979
10:5525145:T:A	F20L	0.979
10:5525145:T:G	F20L	0.979
10:5525192:T:A	V36D	0.979
10:5525509:T:C	F142L	0.979
10:5525511:T:A	F142L	0.979
10:5525511:T:G	F142L	0.979
10:5525168:T:G	I28S	0.978
10:5525354:T:C	F90S	0.978
10:5525291:T:G	F69C	0.976

dbSNP variants (sampled 300 via entrez): RS1000009372 (10:5523959 G>A,C,T), RS1001699674 (10:5527125 G>A), RS1002170992 (10:5526905 TGG>T), RS1002503067 (10:5525777 C>CCTCCCCA), RS1002555584 (10:5525999 T>C), RS1002749925 (10:5526008 G>A), RS1003107383 (10:5525783 C>A,G,T), RS1003683207 (10:5524719 G>A), RS1004143521 (10:5524913 G>A,C,T), RS1004460541 (10:5523066 A>G), RS1005148926 (10:5527250 T>C), RS1005262012 (10:5527083 C>A), RS1006113818 (10:5523917 G>A), RS1006547061 (10:5526542 T>G), RS1006597448 (10:5526387 C>T)

Disease associations

OMIM: gene MIM:114184 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012046_5	Fasting insulin	3.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5169127 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 27,339 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL126	LINEZOLID	4	27,339

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 5 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.30	IC50	500	nM	CHEMBL5183837
5.89	IC50	1300	nM	CHEMBL5202730
5.70	IC50	2000	nM	CHEMBL5189056
5.03	IC50	9300	nM	LINEZOLID

PubChem BioAssay actives

4 with measured affinity, of 5 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(5R)-3-[3-fluoro-4-[4-(1-methylpyridin-1-ium-4-yl)phenyl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one chloride	1852696: Inhibition of CALML3 (unknown origin) assessed as apparent protein translation inhibition constant incubated for 5 hrs by SDS gel electrophoresis	ic50	0.5000	uM
(5R)-3-(3-fluoro-4-pyridin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one	1852696: Inhibition of CALML3 (unknown origin) assessed as apparent protein translation inhibition constant incubated for 5 hrs by SDS gel electrophoresis	ic50	1.3000	uM
(5R)-3-[3-fluoro-4-[3-(hydroxymethyl)phenyl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one	1852696: Inhibition of CALML3 (unknown origin) assessed as apparent protein translation inhibition constant incubated for 5 hrs by SDS gel electrophoresis	ic50	2.0000	uM
Linezolid	1852696: Inhibition of CALML3 (unknown origin) assessed as apparent protein translation inhibition constant incubated for 5 hrs by SDS gel electrophoresis	ic50	9.3000	uM

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases expression, decreases expression	2
Benzo(a)pyrene	decreases expression, increases methylation, affects methylation	2
Tobacco Smoke Pollution	increases expression, affects expression, decreases expression	2
Particulate Matter	decreases expression, increases abundance	2
sodium arsenate	decreases expression, increases abundance	1
beta-lapachone	decreases expression	1
arsenite	increases methylation	1
hydroquinone	decreases expression	1
seocalcitol	increases expression	1
2-palmitoylglycerol	increases expression	1
Arsenic	decreases expression, increases abundance	1
Cadmium	increases abundance, decreases expression	1
Calcitriol	increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Smoke	increases expression, increases abundance	1
Valproic Acid	increases methylation	1
Isotretinoin	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Simvastatin	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5107418	Binding	Inhibition of CALML3 (unknown origin) assessed as apparent protein translation inhibition constant incubated for 5 hrs by SDS gel electrophoresis	Structure-Uptake Relationship Studies of Oxazolidinones in Gram-Negative ESKAPE Pathogens. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.